the market?
Theravance, Inc.
NASDAQ: THRX
36.24
-0.54
(-1.47%)
| Today's Open | $36.62 |
|---|---|
| Previous Close | $36.78 |
| Daily Range | $36.04 - $36.62 |
| 52-Week Range | $17.06 - $42.41 |
| Market Cap | $3.6B |
| P/E Ratio | -24.20 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,073,602 |
| Average Daily Volume | 2,296,150 |
| Current FY EPS | -$1.79 |
How do you think THRX
will perform against the market?
Top THRX Bull/Bear Pitches
zzlangerhans (< 20)
Submitted
August 18, 2011
When I pooh poohed Theravance almost a year ago, televancin was the lead story and it wasn't a pretty one. Televancin sales and royalties for skin infections were dismal. Meanwhile the FDA had rejecte … More
zzlangerhans (< 20)
Submitted
September 25, 2010
The recent bull charge has carried several baby biotechs and small pharmas out of their trading range without positive catalysts, which primes them for disproportionate drops as soon as the momentum i … More
News & Commentary
When Savvy Dealmaking Borders on Reckless Spending
Is Elan deftly making deals or blowing its newfound cash hoard?The 3 Deadliest Diseases in the U.S.
These deadly diseases kill more than 1 million Americans every year. But there's still some good news.Who Benefits From This Market Moving Biotechnology Partnership?
Who Benefits From This Market Moving Biotechnology Partnership?Diversifying Royalties at a Hefty Cost
Elan buys 21% of Thervance's royalties on Glaxo's lung drugs.Sector
Healthcare
Industry
Drugs
Theravance, Inc. (THRX) Description
A biopharmaceutical company focuses on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Website: http://www.theravance.com/
CEO Rating by Glassdoor
More details for Theravance Jobs
Theravance reviews from employees
